2. Search Result
Search Result
Results for "

Eribulin

" in MedChemExpress (MCE) Product Catalog:

8

Inhibitors & Agonists

1

Inhibitory Antibodies

1

Isotope-Labeled Compounds

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-13442
    Eribulin
    1 Publications Verification

    B1939; E7389; ER-086526

    		 Microtubule/Tubulin Apoptosis ADC Cytotoxin Cancer
    Eribulin (E7389) is a microtubule targeting agent that is used for the research of metastatic breast cancer. Eribulin inhibits the proliferation of cancer cells by binding microtubule proteins and microtubules.
    <em>Eribulin</em>
  • HY-13442AS
    Eribulin-d3 mesylate

    		Microtubule/Tubulin Apoptosis Cancer
    Eribulin-d3 (mesylate) is a deuterium labeled Eribulin mesylate. Eribulin mesylate is a microtubule targeting agent that is used for the research of cancer[1][2].
    <em>Eribulin</em>-d3 mesylate
  • HY-13442A
    Eribulin mesylate
    1 Publications Verification

    B1939 mesylate; E7389 mesylate; ER-086526 mesylate

    		 Microtubule/Tubulin Apoptosis Cancer
    Eribulin (E7389) mesylate is a microtubule targeting agent that is used for the research of metastatic breast cancer. Eribulin mesylate inhibits the proliferation of cancer cells by binding microtubule proteins and microtubules.
    <em>Eribulin</em> mesylate
  • HY-156687
    GGFG-Eribulin

    		Drug-Linker Conjugates for ADC Cancer
    GGFG-Eribulin (Compound GGFG) is a Drug-Linker Conjugates for ADC. GGFG-Eribulin consists of the ADC Cytotoxin Eribulin (HY-13442) and a linker. GGFG-Eribulin can be used for synthesis of ADCs .
    GGFG-<em>Eribulin</em>
  • HY-128870
    Mal-PEG2-VCP-Eribulin

    		Drug-Linker Conjugates for ADC Cancer
    Mal-PEG2-VCP-Eribulin consists the ADCs linker (Mal-PEG2-VCP) and Eribulin (HY-13442). Eribulin is a mechanistically unique microtubule inhibitor and Eribulin inhibits the proliferation of cancer cells by binding microtubule proteins and microtubules. Mal-PEG2-VCP-Eribulin is an Eribulin-based agent for antibody conjugates .
    Mal-PEG2-VCP-<em>Eribulin</em>
  • HY-139642
    Mal-(CH2)5-Val-Cit-PAB-Eribulin

    		Drug-Linker Conjugates for ADC Cancer
    Mal-(CH2)5-Val-Cit-PAB-Eribulin is a agent-linker conjugate for ADC with potent antitumor activity by using the anti-microtubule agent, Eribulin, linked via linker Mal-(CH2)5-Val-Cit-PAB .
    Mal-(CH2)5-Val-Cit-PAB-<em>Eribulin</em>
  • HY-128871
    VCP-Eribulin

    		Drug-Linker Conjugates for ADC Cancer
    VCP-Eribulin consists the ADCs linker (VCP) and Eribulin . Eribulin is a mechanistically unique microtubule inhibitor for cancer . VCP-Eribulin is an Eribulin-based agent for antibody conjugates .
    VCP-<em>Eribulin</em>
  • HY-P99612
    Farletuzumab ecteribulin

    MORAb-202

    		 Antibody-Drug Conjugates (ADCs) Cancer
    Farletuzumab ecteribulin (MORAb-202) is an antibody-drug conjugate (ADC), consisting of the humanized anti-human folate receptor alpha (FRA) antibody Farletuzumab (HY-P99153) conjugated via reduced interchain disulfide bonds to Mal-PEG2-Val-Cit-PAB-eribulin. Farletuzumab ecteribulin has a agent-to-antibody ratio of 4.0. Farletuzumab ecteribulin is highly cytotoxic to FRA-positive cells in vitro. Farletuzumab ecteribulin has potent antitumor activity.
    Farletuzumab ecteribulin

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: